385
Participants
Start Date
June 30, 2022
Primary Completion Date
August 23, 2024
Study Completion Date
August 26, 2024
Placebo
Matching placebo, oral (tablet), once per day for 6 weeks
Emraclidine 10 mg
Emraclidine 10 mg, oral (tablet), once per day for 6 weeks
Emraclidine 30 mg
Emraclidine 30 mg, oral (tablet), once per day for 6 weeks
Vratsa, Vratsa, Vratsa
Veliko Tarnovo, Veliko Tarnovo
Veliko Tarnovo, Veliko Tarnovo, Veliko Tarnovo
Stara Zagora, Stara Zagora
North Canton, Ohio, North Canton
Richardson, Texas, Richardson
San Diego, California, San Diego
Little Rock, Arkansas, Little Rock
Anaheim, California, Anaheim
Garden Grove, California, Garden Grove
Lemon Grove, California, Lemon Grove
Montclair, California, Montclair
Riverside, California, Riverside
Hialeah, Florida, Hialeah
Hollywood, Florida, Hollywood
Mangonia Park, Florida, Mangonia Park
Oakland Park, Florida, Oakland Park
Atlanta, Georgia, Atlanta
Decatur, Georgia, Decatur
Shreveport, Louisiana, Shreveport
Gaithersburg, Maryland, Gaithersburg
Flowood, Mississippi, Flowood
DeSoto, Texas, DeSoto
Houston, Texas, Houston
Irving, Texas, Irving
Lead Sponsor
AbbVie
INDUSTRY